Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDC-9 Inactivated Rotavirus Vaccine in Healthy Adults
NCT06485258Phase 1Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CDC-9 Inactivated Rotavirus Vaccine in rotavirus infection (2 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Any unsolicited adverse events at Day 29, Any serious adverse events at Day 237 and 4 more. Started Aug 2024; status: completed.
02
Drugs
CDC-9 Inactivated Rotavirus Vaccine
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT06485258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485258.